Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

NCT02658981 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma
Gliosarcoma
Recurrent Brain Neoplasm

Interventions

BIOLOGICAL: Anti-LAG-3 Monoclonal Antibody BMS 986016
BIOLOGICAL: Anti-PD-1
OTHER: Pharmacological Study
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Anti-CD137

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]